formulary exclusion – Talk Bio

Actionable Insights Powered by AI

J&J’s Stelara Revenue Plummets as Biosimilar Competition Intensifies in 2025

1 day ago talkbio0Tagged Autoimmune Diseases, Benefit, Biosimilars, drug price, formulary exclusion, Johnson & Johnson, manager, Pharmaceutical Services, Revenue Decline, Stelara, ustekinumab

Stelara; Johnson & Johnson; ustekinumab; biosimilars; revenue decline; Q2 2025; pharmacy benefit managers; formulary exclusion; drug pricing; autoimmune disease